BioXcel Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
BioXcel Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2017 to 2023.
  • BioXcel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$13.7M, a 73% increase year-over-year.
  • BioXcel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$71M, a 66.4% increase year-over-year.
  • BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$179M, a 8.02% decline from 2022.
  • BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$166M, a 55% decline from 2021.
  • BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$107M, a 30.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$179M -$13.3M -8.02% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-22
2022 -$166M -$58.8M -55% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-22
2021 -$107M -$24.8M -30.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$82.2M -$49.2M -149% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-11
2019 -$33M -$13.7M -71.1% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-12
2018 -$19.3M -$14.7M -325% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-09
2017 -$4.54M Jan 1, 2017 Dec 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.